Suvaxyn CSF Marker
classical swine fever vaccine (live recombinant)
Table of contents
Overview
Suvaxyn CSF Marker is a veterinary vaccine used to protect pigs against outbreaks of classical swine fever (CSF), a very severe and highly contagious viral disease of both wild and domestic pigs. This disease causes fever, skin lesions, convulsions and often leads to death of the animals. It is also used to protect breeding sows in order to reduce infection of their unborn piglets by classical swine fever virus (CSFV).
Suvaxyn CSF Marker contains live bovine viral diarrhoea virus (BVDV) which has been modified to replace the envelope (E2) gene of BVDV with the corresponding gene of CSFV.
Authorisation details
Product details | |
---|---|
Name |
Suvaxyn CSF Marker
|
Agency product number |
EMEA/V/C/002757
|
Active substance |
Live Recombinant E2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus E2 gene (CP7_E2alf)
|
International non-proprietary name (INN) or common name |
classical swine fever vaccine (live recombinant)
|
Species |
Pigs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AD04
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
10/02/2015
|
Contact address |
Rue Laid Burniat 1 |
Product information
16/08/2021 Suvaxyn CSF Marker - EMEA/V/C/002757 - II/0009
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Live viral vaccines
-
Immunologicals for suidae
Therapeutic indication
For active immunisation of pigs from 7 weeks of age onwards to prevent mortality and reduce infection and disease caused by classical swine fever virus (CSFV).
Onset of immunity: 14 days after vaccination
Duration of immunity: at least 6 months after vaccination
For active immunisation of breeding females to reduce transplacental infection caused by CSFV.
Onset of immunity: 21 days after vaccination
Duration of immunity has not been demonstrated.